ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

Why INT017805 is on this study

  • The record lists it as a treatment, written “LXI-15029”.
  • Claude Opus 5.5 judged it tested: part of what the study tests. Nov 10, 2026, 1:16 PM UTC
  • The role rule says the same.
  • So INT017805's page lists this study under “Testing it”.
3 links0 made here, not in the record7 judgments2 judges (the rules as one: Rule based)2 record changes seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.gov
Oct 19Oct 26Nov 2Nov 9Nov 16Nov 23TodayNCT03125746A Study of LXI-15029 inPatients With AdvancedMalignant Solid TumorsShandong Luoxin PharmaceuticalPhase 1 · completedRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedNov 19 · ClinicalTrials.gov record · Version of 2026-11-19Nov 20 · Rule based · Reading keptReading keptCONDITIONSBreast NeoplasmsNo longer in the registry's filing›Nov 14 · Rule based · Finest filed termAs of now · Rule based · Main conditionMain conditionDRUGSINT017805Entry “LXI-15029”, read by our name r…›Nov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · TestedTestedExemestaneEntry “LXI-15029+Exemestane”, read by…›Nov 10 · Claude Opus 5.5 · Background · partnerNov 18 · Rule based · TestedTested

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

All judgments on this study

WhenLinkJudgeDecisionState
1 version of the record seen on ClinicalTrials.gov, Nov 19 · changes seen, not judgments
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10INT017805Claude Opus 5.5TestedCurrent
Nov 10ExemestaneClaude Opus 5.5Background · partnerCurrent
Nov 14Breast NeoplasmsRule based · condition-kind ruleFinest filed termCurrent
Nov 18INT017805Rule based · role ruleTestedAgrees
Nov 18ExemestaneRule based · role ruleTestedCurrent
Nov 20The record itselfRule based · nightly checkReading keptCurrent
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.

How a condition link is counted

For each condition a study is filed under: whether it is the study's own condition at the finest the study states it, a wider one, a general category, or filed by mistake; and whether it is the main condition, a setting the study names, or only how it was filed.

A decision on file for one study overrides it, with who made it and when.

When a study changes after it was read

Every night, studies whose record changed are compared with the last reading. A change to sites or dates leaves the reading as it is; a reworded entry keeps it; a change to the treatments or conditions marks it to be read again.

Until it is read again, the page shows the last reading and says so.